| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 41 | 2025 | 1122 | 9.780 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 43 | 2024 | 429 | 7.600 |
Why?
|
| Carcinoma, Hepatocellular | 25 | 2025 | 1006 | 5.220 |
Why?
|
| Liver Neoplasms | 26 | 2025 | 1416 | 4.690 |
Why?
|
| Hepatitis C, Chronic | 19 | 2023 | 373 | 4.520 |
Why?
|
| Hepatitis C | 15 | 2023 | 389 | 4.190 |
Why?
|
| End Stage Liver Disease | 21 | 2024 | 202 | 3.830 |
Why?
|
| Liver Diseases, Alcoholic | 10 | 2023 | 59 | 3.430 |
Why?
|
| Liver Cirrhosis | 35 | 2025 | 948 | 3.170 |
Why?
|
| Antiviral Agents | 18 | 2023 | 825 | 2.620 |
Why?
|
| Hepacivirus | 13 | 2023 | 273 | 2.480 |
Why?
|
| Waiting Lists | 13 | 2024 | 241 | 2.150 |
Why?
|
| Fatty Liver | 10 | 2025 | 215 | 2.040 |
Why?
|
| Tissue and Organ Procurement | 7 | 2025 | 248 | 2.020 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 385 | 1.940 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 396 | 1.930 |
Why?
|
| Tissue Donors | 10 | 2025 | 507 | 1.930 |
Why?
|
| Nutrition Surveys | 23 | 2025 | 313 | 1.820 |
Why?
|
| United States | 62 | 2025 | 11798 | 1.570 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 362 | 1.550 |
Why?
|
| Betacoronavirus | 5 | 2020 | 306 | 1.430 |
Why?
|
| Hepatitis, Alcoholic | 5 | 2025 | 34 | 1.380 |
Why?
|
| Humans | 146 | 2025 | 134225 | 1.280 |
Why?
|
| Pandemics | 15 | 2024 | 1193 | 1.160 |
Why?
|
| Hospitalization | 13 | 2024 | 1919 | 1.160 |
Why?
|
| Retrospective Studies | 46 | 2025 | 17591 | 1.140 |
Why?
|
| Risk Factors | 37 | 2025 | 11196 | 1.130 |
Why?
|
| Graft Survival | 9 | 2025 | 482 | 1.070 |
Why?
|
| Organ Transplantation | 2 | 2020 | 183 | 1.060 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 86 | 1.050 |
Why?
|
| Adult | 57 | 2025 | 31962 | 1.030 |
Why?
|
| Middle Aged | 56 | 2025 | 29430 | 1.000 |
Why?
|
| Prevalence | 22 | 2025 | 2685 | 0.960 |
Why?
|
| Alcohol Drinking | 3 | 2023 | 388 | 0.900 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2024 | 140 | 0.890 |
Why?
|
| Liver | 11 | 2025 | 1876 | 0.880 |
Why?
|
| Mortality | 4 | 2021 | 261 | 0.850 |
Why?
|
| Transplant Recipients | 3 | 2021 | 227 | 0.840 |
Why?
|
| Male | 67 | 2025 | 66215 | 0.810 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2023 | 50 | 0.810 |
Why?
|
| Liver Failure | 3 | 2017 | 91 | 0.790 |
Why?
|
| Aged | 34 | 2025 | 21822 | 0.780 |
Why?
|
| Length of Stay | 8 | 2025 | 1392 | 0.780 |
Why?
|
| Cause of Death | 15 | 2025 | 506 | 0.770 |
Why?
|
| Proton Pump Inhibitors | 3 | 2020 | 285 | 0.760 |
Why?
|
| Female | 66 | 2025 | 72054 | 0.750 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 483 | 0.750 |
Why?
|
| Coinfection | 2 | 2023 | 183 | 0.720 |
Why?
|
| Drug Overdose | 2 | 2020 | 75 | 0.720 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2025 | 245 | 0.710 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2020 | 88 | 0.700 |
Why?
|
| Hepatic Encephalopathy | 5 | 2025 | 94 | 0.640 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 35 | 0.640 |
Why?
|
| Gastrectomy | 2 | 2017 | 103 | 0.620 |
Why?
|
| Liver Diseases | 5 | 2023 | 392 | 0.610 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 243 | 0.610 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 24 | 0.600 |
Why?
|
| Probiotics | 1 | 2021 | 229 | 0.590 |
Why?
|
| DNA, Viral | 2 | 2018 | 500 | 0.560 |
Why?
|
| Severity of Illness Index | 12 | 2025 | 3119 | 0.550 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 14 | 0.540 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 938 | 0.540 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 58 | 0.530 |
Why?
|
| Portal Vein | 1 | 2017 | 95 | 0.520 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 6 | 0.510 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1100 | 0.510 |
Why?
|
| Time Factors | 13 | 2024 | 6595 | 0.510 |
Why?
|
| Transplants | 1 | 2016 | 37 | 0.500 |
Why?
|
| Secondary Prevention | 1 | 2017 | 225 | 0.490 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3172 | 0.490 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 173 | 0.470 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 2093 | 0.470 |
Why?
|
| Health Care Costs | 4 | 2024 | 409 | 0.470 |
Why?
|
| Hospital Costs | 1 | 2016 | 187 | 0.450 |
Why?
|
| HIV Infections | 3 | 2025 | 2073 | 0.450 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 303 | 0.440 |
Why?
|
| Databases, Factual | 8 | 2022 | 1260 | 0.440 |
Why?
|
| Proportional Hazards Models | 8 | 2025 | 1486 | 0.430 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 823 | 0.420 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 271 | 0.410 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2023 | 45 | 0.400 |
Why?
|
| HIV | 2 | 2025 | 193 | 0.390 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 121 | 0.390 |
Why?
|
| Risk Assessment | 13 | 2024 | 3754 | 0.390 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 21 | 0.390 |
Why?
|
| Treatment Outcome | 17 | 2025 | 13105 | 0.390 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2025 | 73 | 0.390 |
Why?
|
| Young Adult | 13 | 2025 | 9963 | 0.370 |
Why?
|
| Patient Readmission | 3 | 2020 | 430 | 0.370 |
Why?
|
| Laparoscopy | 1 | 2017 | 520 | 0.360 |
Why?
|
| Cross-Sectional Studies | 11 | 2025 | 3759 | 0.360 |
Why?
|
| Cohort Studies | 8 | 2025 | 5225 | 0.360 |
Why?
|
| Ascites | 4 | 2025 | 111 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1144 | 0.350 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 7244 | 0.340 |
Why?
|
| Health Policy | 2 | 2025 | 233 | 0.340 |
Why?
|
| Incidence | 7 | 2025 | 3424 | 0.320 |
Why?
|
| Registries | 4 | 2019 | 1588 | 0.300 |
Why?
|
| Hypothyroidism | 2 | 2020 | 100 | 0.290 |
Why?
|
| Disease Progression | 7 | 2025 | 2265 | 0.290 |
Why?
|
| Inpatients | 4 | 2020 | 551 | 0.280 |
Why?
|
| Health Status Disparities | 3 | 2020 | 252 | 0.280 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 285 | 0.270 |
Why?
|
| Recurrence | 3 | 2021 | 1470 | 0.270 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2025 | 80 | 0.270 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 575 | 0.260 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 139 | 0.230 |
Why?
|
| Preoperative Period | 3 | 2020 | 93 | 0.230 |
Why?
|
| Cholangitis | 1 | 2025 | 40 | 0.230 |
Why?
|
| Troponin | 1 | 2025 | 79 | 0.230 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 66 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 759 | 0.220 |
Why?
|
| Organ Preservation | 1 | 2025 | 48 | 0.220 |
Why?
|
| Pulse Wave Analysis | 1 | 2024 | 51 | 0.220 |
Why?
|
| Donor Selection | 1 | 2024 | 58 | 0.220 |
Why?
|
| Depression | 3 | 2023 | 1365 | 0.220 |
Why?
|
| Hepatitis A | 1 | 2024 | 32 | 0.220 |
Why?
|
| Republic of Korea | 1 | 2024 | 52 | 0.210 |
Why?
|
| Perfusion | 1 | 2025 | 214 | 0.210 |
Why?
|
| Telemedicine | 2 | 2023 | 507 | 0.210 |
Why?
|
| Age Distribution | 3 | 2019 | 445 | 0.210 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 33 | 0.210 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 80 | 0.200 |
Why?
|
| Policy | 1 | 2023 | 37 | 0.200 |
Why?
|
| Adolescent | 6 | 2024 | 20647 | 0.200 |
Why?
|
| California | 2 | 2020 | 144 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 344 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 1070 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2021 | 277 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 401 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 606 | 0.190 |
Why?
|
| Integrases | 1 | 2023 | 163 | 0.190 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 121 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 27 | 0.180 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2023 | 80 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2023 | 173 | 0.180 |
Why?
|
| Prebiotics | 1 | 2021 | 29 | 0.180 |
Why?
|
| Alcohol Abstinence | 1 | 2021 | 17 | 0.180 |
Why?
|
| Viremia | 1 | 2022 | 134 | 0.180 |
Why?
|
| Cholestasis | 1 | 2023 | 157 | 0.180 |
Why?
|
| Military Personnel | 1 | 2023 | 204 | 0.180 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 15 | 0.180 |
Why?
|
| Health Care Rationing | 1 | 2021 | 63 | 0.180 |
Why?
|
| Hypernatremia | 1 | 2021 | 32 | 0.170 |
Why?
|
| Tacrolimus | 1 | 2021 | 107 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2021 | 75 | 0.170 |
Why?
|
| Age Factors | 4 | 2024 | 2997 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 32 | 0.170 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 322 | 0.170 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 142 | 0.170 |
Why?
|
| Prediabetic State | 1 | 2021 | 63 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2021 | 56 | 0.170 |
Why?
|
| Peritonitis | 2 | 2017 | 80 | 0.170 |
Why?
|
| Biliary Atresia | 1 | 2023 | 206 | 0.170 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 19 | 0.170 |
Why?
|
| Exercise | 3 | 2021 | 875 | 0.170 |
Why?
|
| Dysbiosis | 1 | 2021 | 145 | 0.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 81 | 0.170 |
Why?
|
| Acute Kidney Injury | 2 | 2025 | 704 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2021 | 185 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1493 | 0.160 |
Why?
|
| Thyroid Gland | 1 | 2020 | 117 | 0.160 |
Why?
|
| Causality | 1 | 2019 | 94 | 0.160 |
Why?
|
| Methadone | 1 | 2020 | 126 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1317 | 0.160 |
Why?
|
| Entamoebiasis | 1 | 2019 | 3 | 0.150 |
Why?
|
| Entamoeba histolytica | 1 | 2019 | 14 | 0.150 |
Why?
|
| Fibrosis | 4 | 2024 | 461 | 0.150 |
Why?
|
| Phenols | 1 | 2019 | 57 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 33 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 466 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 244 | 0.150 |
Why?
|
| Colonic Diseases | 1 | 2019 | 38 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 68 | 0.150 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 54 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2019 | 331 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 365 | 0.140 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 32 | 0.140 |
Why?
|
| Rifamycins | 1 | 2017 | 22 | 0.140 |
Why?
|
| Licensed Practical Nurses | 1 | 2017 | 1 | 0.140 |
Why?
|
| Bacterial Infections | 2 | 2017 | 329 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2017 | 21 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 680 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 328 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 57 | 0.130 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 33 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 35 | 0.130 |
Why?
|
| Thrombophilia | 1 | 2017 | 42 | 0.130 |
Why?
|
| Carbamates | 1 | 2017 | 68 | 0.130 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2016 | 3 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 207 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 739 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2020 | 251 | 0.130 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 94 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 292 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5466 | 0.120 |
Why?
|
| Income | 1 | 2016 | 140 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 214 | 0.120 |
Why?
|
| Heparin | 1 | 2017 | 230 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3678 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2017 | 324 | 0.120 |
Why?
|
| Educational Status | 1 | 2016 | 298 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1205 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2915 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2022 | 1595 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2016 | 145 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 176 | 0.120 |
Why?
|
| Health Resources | 1 | 2016 | 127 | 0.110 |
Why?
|
| Heterozygote | 1 | 2017 | 732 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 319 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 221 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 772 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 255 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 657 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 2214 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2016 | 397 | 0.110 |
Why?
|
| Allografts | 2 | 2025 | 199 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 626 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 1788 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 1404 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 492 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 701 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 906 | 0.090 |
Why?
|
| Morbidity | 2 | 2023 | 256 | 0.090 |
Why?
|
| Comorbidity | 3 | 2023 | 1628 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 6617 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 54 | 0.080 |
Why?
|
| Medicaid | 2 | 2023 | 254 | 0.080 |
Why?
|
| Prognosis | 4 | 2023 | 5085 | 0.080 |
Why?
|
| ROC Curve | 2 | 2023 | 614 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 108 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 567 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1222 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 1251 | 0.080 |
Why?
|
| Censuses | 2 | 2019 | 11 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2204 | 0.080 |
Why?
|
| Child | 3 | 2024 | 25917 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1388 | 0.070 |
Why?
|
| Biopsy | 2 | 2023 | 1303 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 723 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 224 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 2163 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2024 | 1003 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2024 | 1722 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2021 | 1338 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2592 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2025 | 893 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1909 | 0.060 |
Why?
|
| Prednisolone | 1 | 2025 | 74 | 0.060 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 26 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 563 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 30 | 0.060 |
Why?
|
| Agent Orange | 1 | 2023 | 4 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1183 | 0.050 |
Why?
|
| Neoplasms | 1 | 2019 | 3036 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 125 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2023 | 804 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 104 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2319 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 101 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 6350 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 105 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 60 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 116 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 169 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 87 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 91 | 0.050 |
Why?
|
| Acute Disease | 1 | 2025 | 1190 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 202 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 134 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 560 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2025 | 568 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 125 | 0.040 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 8 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 493 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 308 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 86 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 144 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 36526 | 0.040 |
Why?
|
| Obesity | 2 | 2024 | 2449 | 0.040 |
Why?
|
| Death Certificates | 1 | 2019 | 11 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 162 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 715 | 0.040 |
Why?
|
| Paromomycin | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 91 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2018 | 62 | 0.040 |
Why?
|
| Weight Loss | 1 | 2023 | 518 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 105 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 42 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 833 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 417 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 624 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 46 | 0.040 |
Why?
|
| Myositis | 1 | 2019 | 106 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 480 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 13 | 0.030 |
Why?
|
| Patient Portals | 1 | 2017 | 20 | 0.030 |
Why?
|
| Computer Security | 1 | 2017 | 29 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 99 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 416 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2016 | 8 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 138 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 249 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 106 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2017 | 62 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 257 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 129 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2018 | 246 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 284 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 543 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 298 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 311 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 373 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 574 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3434 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 542 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 464 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1512 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 725 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 452 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 479 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 1043 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1436 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1419 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 734 | 0.030 |
Why?
|
| Anxiety | 1 | 2020 | 1004 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1721 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2016 | 402 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1344 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1982 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1739 | 0.020 |
Why?
|
| Communication | 1 | 2017 | 542 | 0.020 |
Why?
|
| Diet | 1 | 2020 | 1195 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8640 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13263 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 14897 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7600 | 0.010 |
Why?
|